Review highlights model gap in neutrophilic asthma research: full analysis

A new Molecular Medicine review spotlights a stubborn problem in severe asthma research: neutrophilic asthma is clinically important, mechanistically distinct, and often resistant to standard corticosteroids, yet the field still lacks experimental models that fully reflect the human disease. According to the review by Jialin Yao, Jingjing Lu, and Jing Gao, that gap has limited both pathogenesis research and the translation of promising therapies into practice. (pubmed.ncbi.nlm.nih.gov)

That concern isn’t new, but it’s becoming more urgent. Recent reviews describe neutrophilic asthma as a type 2-low phenotype marked by late onset, worse symptom control, more frequent exacerbations, and reduced steroid responsiveness. Estimates vary depending on how sputum neutrophilia is defined, but one 2025 review placed prevalence at roughly 16% to 28% of adults with asthma. Environmental exposures, smoking, obesity, infection, and airway irritants have all been implicated in shaping this endotype, adding to the challenge of building models that are both reproducible and clinically relevant. (pubmed.ncbi.nlm.nih.gov)

The review’s central contribution is its focus on model systems, both animal and cell-based. Across the literature, murine systems remain dominant, including allergen-plus-LPS protocols, pollutant- or irritant-driven models, and steroid-resistant variants designed to better mimic refractory disease. These models have helped define pathways involving Th17 signaling, inflammasome activation, neutrophil extracellular traps, epithelial-immune crosstalk, and airway structural cell participation. But they also come with tradeoffs: many capture only slices of the disease, and few fully reproduce the heterogeneity seen in patients. (pubmed.ncbi.nlm.nih.gov)

That limitation matters because the therapeutic pipeline is still unsettled. Reviews and preclinical studies point to a wide range of potential targets, including IL-17-related pathways, NLRP3 inflammasome signaling, CTSS, PD-1 modulation, and NET-associated biology. Some experimental interventions have shown encouraging effects in mouse models, including reduced airway neutrophilia or improved steroid responsiveness, but the broader field still lacks a clear, validated path to routine clinical translation. In that sense, the Molecular Medicine review is less a celebration of breakthrough therapies than a call for better tools to test them. (pubmed.ncbi.nlm.nih.gov)

Expert commentary across recent reviews lands in a similar place. Authors writing in Journal of Clinical Medicine, Immunology & Cell Biology, and other journals have emphasized that neutrophilic asthma remains undercharacterized compared with eosinophilic disease, despite its association with severe, poorly controlled illness. Several reviews also note that biomarker thresholds, disease definitions, and model design still vary substantially across studies, making cross-comparison difficult and slowing consensus around the most actionable targets. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, this is a useful translational signal. Comparative airway disease research often relies on experimental systems to bridge mechanism and treatment, and this review reinforces how much model choice influences what the field believes about disease biology. Better neutrophilic asthma models could improve not just human respiratory drug discovery, but also comparative work in naturally occurring animal airway disease, including efforts to understand steroid-insensitive inflammation, airway remodeling, and host-environment interactions across species. The veterinary relevance is less about immediate practice change and more about research direction: stronger models usually mean stronger translational confidence. (nature.com)

What to watch: The next phase will likely center on refining models that combine mechanistic precision with clinical realism, including systems that better reflect mixed exposures, chronicity, and treatment resistance. Watch, too, for more use of advanced in vitro platforms and comparative animal data to validate whether preclinical signals truly map onto real disease. If the field can standardize how it defines and models neutrophilic asthma, therapeutic translation may finally move faster. (pubmed.ncbi.nlm.nih.gov)